MarginsXMarginsX
Home › Markets › Health Care › AMRX

Amneal Pharmaceuticals Inc. (AMRX)

AMRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$21.23
-0.70% on the day
Market cap
$7.4B
Mid cap
Revenue · 2025
$3.0B
+8.0% on 2024
Net income · 2025
$72.1M
2.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/0001723128-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAMRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001723128
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$3.0B
Net income$72.1M
Operating income$394.1M
Net margin2.4%
Operating margin13.1%
Revenue growth+8.0%
Cash$282.0M
Total assets$3.7B
P/E (computed)102.7×
P/S (computed)2.5×

Warning signs

Cash runway
Cash-flow positive
$157.4M cash at September 30, 2026
Share count, 1 year
+10.8%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$9.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$157.4M cash; operating cash flow $45.2M a quarter.Report 2026-09-30
Shares outstanding348,412,726 (2026-10-30); 314,362,920 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $9.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$862.7M-$21.7M$98.3M$157.4M$2.9B$3.2B10-Q 2026-11-09
Q2 2026
2026-06-30
$796.2M$57.7M-$21.2M$127.6M$2.6B$3.1B10-Q 2026-08-06
Q1 2026
2026-03-31
$722.5M$62.3M-$26.7M$197.7M$2.6B$3.0B10-Q 2026-05-07
Q4 2025
2025-12-31
$814.3M$35.1M$130.3M$282.0M$2.6B$3.0B10-K 2026-02-27
Q3 2025
2025-09-30
$784.5M$2.4M$118.5M$201.2M$2.6B$2.9B10-Q 2026-11-09
Q2 2025
2025-06-30
$724.5M$22.4M$83.8M$71.5M$2.2B$2.9B10-Q 2026-08-06
Q1 2025
2025-03-31
$695.4M$12.2M$7.4M$59.2M$2.2B$2.8B10-Q 2026-05-07
Q4 2024
2024-12-31
$730.5M-$31.1M$118.1M$110.6M$2.4B$2.8B10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-09-03
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-07-30

Source: SEC EDGAR submissions feed, 695 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.2%
1 month+9.2%
3 months+23.8%
Year to date+69.7%
1 year+85.6%
From 52-week high-1.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
ABVXAbivax SA$83.61-4.53%$7.3B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier